Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2015, Article ID 978194, 8 pages
http://dx.doi.org/10.1155/2015/978194
Clinical Study

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

1Department of Urology, Jules Bordet Institute, 1000 Brussels, Belgium
2Ipsen NV, Guldensporenpark 87, 9820 Merelbeke, Belgium

Received 26 November 2014; Accepted 8 January 2015

Academic Editor: James L. Gulley

Copyright © 2015 Alexandre Peltier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Shahani, M. Braga-Basaria, and S. Basaria, “Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 6, pp. 2042–2049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Grossmann, E. J. Hamilton, C. Gilfillan, D. Bolton, D. L. Joon, and J. D. Zajac, “Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy,” Medical Journal of Australia, vol. 194, no. 6, pp. 301–306, 2011. View at Google Scholar · View at Scopus
  3. N. D. Shore, P.-A. Abrahamsson, J. Anderson, E. D. Crawford, and P. Lange, “New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 1, pp. 7–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Schröder, E. D. Crawford, K. Axcrona, H. Payne, and T. E. Keane, “Androgen deprivation therapy: past, present and future,” British Journal of Urology International, vol. 109, supplement 6, pp. 1–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Schenk, A. R. Kristal, K. B. Arnold et al., “Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial,” The American Journal of Epidemiology, vol. 173, no. 12, pp. 1419–1428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Sharifi, J. L. Gulley, and W. L. Dahut, “An update on androgen deprivation therapy for prostate cancer,” Endocrine-Related Cancer, vol. 17, no. 4, pp. R305–R315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Lepor, “The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia,” Reviews in Urology, vol. 8, no. 4, pp. 183–189, 2006. View at Google Scholar
  8. A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013,” European Urology, vol. 65, no. 1, pp. 124–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Chavan, S. Chavan, N. Chavan, and V. Trivedi, “Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study,” Journal of Postgraduate Medicine, vol. 55, no. 1, pp. 17–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Horwich, C. Parker, T. de Reijke, and V. Kataja, “Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 24, no. 6, Article ID mdt208, pp. vi106–vi114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Pinault, B. Tetu, J. Gagnon, G. Monfette, A. Dupont, and F. Labrie, “Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide,” Urology, vol. 39, no. 3, pp. 254–261, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Oesterling, “LHRH agonists: a nonsurgical treatment for benign prostatic hyperplasia,” Journal of Andrology, vol. 12, no. 6, pp. 381–388, 1991. View at Google Scholar · View at Scopus
  13. M. J. Barry, W. O. Williford, Y. Chang et al., “Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?” The Journal of Urology, vol. 154, no. 5, pp. 1770–1774, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. H. A. Guess, “Benign prostatic hyperplasia and prostate cancer,” Epidemiologic Reviews, vol. 23, no. 1, pp. 152–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Hamilton and D. Sharp, “Symptomatic diagnosis of prostate cancer in primary care: a structured review,” British Journal of General Practice, vol. 54, no. 505, pp. 617–621, 2004. View at Google Scholar · View at Scopus
  16. K. Axcrona, S. Aaltomaa, C. M. Da Silva et al., “Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide,” BJU International, vol. 110, no. 11, pp. 1721–1728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Mommsen and L. Petersen, “Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention,” Scandinavian Journal of Urology and Nephrology, vol. 28, no. 4, pp. 401–404, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Klarskov, S. Mommsen, P. Klarskov, and N. Svoldgård, “Endocrine treatment and LUTS in men with prostate cancer,” European Urology, vol. 5, supplement 5, p. 250, 2006. View at Google Scholar
  19. L. L. Klarskov, P. Klarskov, S. Mommsen, and N. Svolgaard, “Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study,” Scandinavian Journal of Urology and Nephrology, vol. 46, no. 1, pp. 37–43, 2012. View at Publisher · View at Google Scholar · View at Scopus